Nanofacile
Montréal, Québec
Accelerate and de-risk nanomedicine therapies R&D for faster, more effective results
Description
Nanofacile is pioneering advancements in nanomedicine by providing a revolutionary "Nanomedicine in a box" solution a kit with everything biotech innovators need to encapsulate their therapies. Nanofacile accelerates and de-risks lipid-based nanoparticle RNA therapies development with advanced, easy-to-use technology. This enables rapid preclinical development using standard lab equipment and targeted lipid nanoparticle formulations. This system significantly reduces the time and risk required for developing nanotherapeutic formulations, allowing for more affordable, fast, and high-throughput R&D. Nanofacile’s innovative approach addresses the traditional bottlenecks in the industry, offering a method that enables encapsulation in just 10 minutes of up to 28 different formulations at the same time. 
Nanofacile offers a comprehensive solution that includes optimized delivery recipes and a proprietary advanced technology, significantly shortening preclinical development from weeks to days! This system is designed to be efficient, user-friendly, and accessible: 
The company is led by Ruben Lopez, Ph.D., an expert in nanotechnology with over 12 years of experience in R&D. Under his leadership, Nanofacile is poised to transform the landscape of nanomedicine by making advanced therapeutic solutions more accessible to researchers and clinicians worldwide.
Financial | Looking for $1M to accelerate and enhance commercialization
Nanofacile will launch their commercialization next year in 2025e and will achieve profitability in 2026e with their two-line products targeted for CRO & ARL, and Biotech & Pharma companies. They plan to achieve double digit million topline as soon as 2027e.
Their business model allows Nanofacile to share 50% of the Intellectual Property (IP) developed with their clients and keep 5% of future royalties on the product. 
Origins of the Project | Addressing a Global Need
The inspiration behind Nanofacile stems from the critical need to improve the efficiency and accessibility of RNA therapies research. Traditional methods are often expensive, slow, and require significant expertise, limiting the potential for widespread adoption and innovation. The inspiration for Nanofacile Inc. began in a biology lab in 2021, where the founder, Dr. Ruben Rodrigo Lopez Salazar, encountered challenges in encapsulating mRNA with an inefficient system. Recognizing the high demand for such technology but limited accessibility, the team aimed to democratize mRNA encapsulation, which led to the formation of the company.
Nanofacile was founded to overcome these challenges by developing a system that is not only cost-effective but also user-friendly, enabling a broader range of researchers to contribute to the advancement of nanomedicine.
With the global market for RNA therapies expected to triple by 2030, Nanofacile is well-positioned to play a crucial role in the expansion and democratization of this field. The company’s focus on high-throughput and efficiency will help drive down costs and accelerate the development of new therapies, benefiting millions of patients worldwide!
Impact
good health and well-being
industry, innovation and infrastructure
Responsible consumption and production
Nanofacile is revolutionizing nanomedicine R&D by reducing costs and development times, making advanced therapies more accessible and accelerating the journey from concept to clinic, helping millions of patients worldwide.
Nanofacile is focused is on reducing preclinical development times and costs by a factor of 10x.
Company
Nanofacile accelerates and de-risks lipid-based nanoparticle gene therapy R&D with advanced, easy-to-use technology enabling rapid preclinical development using standard lab equipment and targeted lipid nanoparticle formulations.
The Team
Ruben Lopez Ph.D.
Founder & CEO
Alejandro Forigua Ph.D.
R&D Lead
Gopi Suresh M.Sc.
R&D Consultant